{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-013688","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.495002+00:00","generated_at":"2026-06-28T16:50:46.076076+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Editas Medicine appoints Bernadette Connaughton to Board of Directors","bullets":["Board expanded to add Bernadette Connaughton as independent director, effective October 26, 2021.","Appointed to Organization, Leadership and Compensation Committee; term until 2023 Annual Meeting.","Ms. Connaughton previously served as President Intercontinental at Bristol-Myers Squibb (1983-2017).","Director compensation: $40,000 annual cash retainer, $5,000 committee fee, and option for 24,732 shares vesting over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-013688","json":"https://secwatch.observer/filing/0001558370-21-013688.json","markdown":"https://secwatch.observer/filing/0001558370-21-013688.md","text":"https://secwatch.observer/filing/0001558370-21-013688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837021013688/0001558370-21-013688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837021013688/edit-20211026x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:50:46.076076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b442c289ed","claim":"Bernadette Connaughton was appointed as Independent Director at Editas Medicine, Inc..","evidence_excerpt":"On October 26, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Bernadette Connaughton as an independent director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837021013688/0001558370-21-013688-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}